세계의 국소 약물전달 시장 : 제품별, 용도별, 최종 사용자별, 지역별 예측(-2030년)

The global topical drug delivery market is expected to reach USD 409.0 billion by 2030 from USD 268.4 billion in 2025, at a CAGR of 8.8% during the forecast period.

The growth of this market can largely be attributed to the uptake of topical prescription therapy for dry eye diseases, the growing focus of pharmaceutical companies on the R&D of innovative transdermal drug delivery systems, the increasing prevalence of skin infections, and the rising preference for non-invasive drug delivery methods.

By product, the semi-solid formulations segment accounted for the largest market share in 2024.

By product, the topical drug delivery market is segmented into semi-solid formulations, liquid formulations, solid formulations, transdermal products, and other products. The large share of the semi-solid formulations segment is attributed to enhanced patient adherence with limited side effects, high absorption, and efficient provision of drug release. These dosage forms are non-dehydrating and do not modify skin functioning, fueling market growth.

By site of application, the dermal drug delivery segment accounted for the largest market share in 2024.

By site of application, the market is segmented into dermal drug delivery, ophthalmic drug delivery, rectal drug delivery, vaginal drug delivery, and nasal drug delivery. The large share of the dermal drug delivery segment can be attributed to the increasing product launches in the market. Fewer regulatory requirements and lower irritation than nasal or ophthalmic drug delivery also contribute to market growth. Dermal drug delivery through nanoemulsions is also suitable for chronic and autoimmune diseases, such as psoriasis and vitiligo.

By region, North America accounted for the largest market share in 2024.

By region, North America accounted for the largest share of the market in 2024. The large share of this region is attributed to the high risk of skin disorders, the rising prevalence of chronic diseases (such as diabetes), increasing use of contraceptives, the increasing geriatric population, and the growing focus of pharmaceutical companies on the R&D of innovative transdermal drug delivery systems.

Breakdown of supply-side primary interviews:

• By Company Type: Tier 1 (45%), Tier 2 (20%), and Tier 3 (35%)
• By Designation: C-level Executives (35%), Directors (25%), and Other Designations (40%)
• By Region: North America (40%), Europe (25%), Asia Pacific (20%), Latin America (10%), and the Middle East & Africa (5%)

Breakdown of demand-side primary interviews:

• By Company Type: Hospitals & Clinics (60%), Ambulatory Surgery Centers (25%), and Home Care Settings (15%)
• By Designation: Directors (35%), Vice Presidents (27%), Managers (22%), and Other Designations (16%)
• By Region: North America (40%), Europe (25%), the Asia Pacific (20%), Latin America (10%), and the Middle East & Africa (5%)

Key players in the Topical Drug Delivery Market

The prominent players in the topical drug delivery market are Johnson & Johnson Private Limited (US), Galderma (Switzerland), Bayer AG (Germany), Novartis International AG (Switzerland), AbbVie Inc. (US), GSK Plc. (UK), Bausch Health Companies Inc. (Canada), Glenmark Pharmaceuticals Ltd. (India), Hisamitsu Pharmaceuticals Inc. (Japan), Cipla (India), Boehringer Ingelheim International GmbH (Germany), Pfizer Inc. (US), Teva Pharmaceuticals Industries Ltd. (Israel), Viatris Inc. (US), Organon group of companies (US), Solventum (US), Crescita Therapeutics Inc. (Canada), Luye Pharma Group (China), Lead Chemical Co., Ltd. (Japan), Purdue Pharma L.P. (US), Lavipharm (Greece), CMP Pharma, Inc. (Germany), Encore Dermatology, Inc. (US), Rusan Pharma Ltd. (India), and AdhexPharma (France).

Research Coverage:

The report analyzes the topical drug delivery market. It aims to estimate the market size and future growth potential of this market based on various segments such as product, site of application, end user, and region. The report also includes a product portfolio matrix of various topical drug delivery products available in the market. The report also provides a competitive analysis of the key players in this market, along with their company profiles, product offerings, and key market strategies.

Reasons to Buy the Report

The report will enrich established firms and new entrants/smaller firms to gauge the market's pulse, which in turn would help them garner a more significant share of the market. Firms purchasing the report could use one or any combination of the following strategies to strengthen their position in the market.

This report provides insights into the following pointers:

• Market Penetration: Comprehensive information on product portfolios offered by the top players in the topical drug delivery market. The report analyzes this market by product, site of application, and end users.
• Product Development/Innovation: Detailed insights on upcoming technologies, R&D activities, and product launches in the topical drug delivery market
• Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various topical drug delivery products across regions.
• Market Diversification: Exhaustive information about products, untapped regions, recent developments, and investments in the topical drug delivery market.
• Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the topical drug delivery market.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
  • 1.2.1 INCLUSIONS & EXCLUSIONS
  • 1.2.2 MARKETS & REGIONS COVERED
  • 1.2.3 YEARS CONSIDERED
  • 1.2.4 CURRENCY CONSIDERED
• 1.3 MARKET STAKEHOLDERS
• 1.4 LIMITATIONS
• 1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
• 2.2 RESEARCH METHODOLOGY DESIGN
  • 2.2.1 SECONDARY DATA
    • 2.2.1.1 Key data from secondary sources
  • 2.2.2 PRIMARY DATA
    • 2.2.2.1 Key data from primary sources
    • 2.2.2.2 Key industry insights
• 2.3 MARKET SIZE ESTIMATION
  • 2.3.1 APPROACH 1: REVENUE SHARE ANALYSIS
  • 2.3.2 APPROACH 2: PHARMACEUTICAL SALES ANALYSIS
  • 2.3.3 APPROACH 3: TOP-DOWN APPROACH
  • 2.3.4 APPROACH 4: BOTTOM-UP APPROACH
  • 2.3.5 APPROACH 4: PRIMARY INTERVIEWS
  • 2.3.6 APPROACH 5: DEMAND-SIDE APPROACH
  • 2.3.7 APPROACH 6: VOLUME DATA ANALYSIS
• 2.4 MARKET BREAKDOWN & DATA TRIANGULATION
• 2.5 MARKET SHARE ANALYSIS
• 2.6 STUDY ASSUMPTIONS
  • 2.6.1 GROWTH RATE ASSUMPTIONS
• 2.7 RISK ASSESSMENT
• 2.8 LIMITATIONS
  • 2.8.1 METHODOLOGY-RELATED LIMITATIONS
  • 2.8.2 SCOPE-RELATED LIMITATIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 TOPICAL DRUG DELIVERY MARKET OVERVIEW
• 4.2 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT & COUNTRY (2024)
• 4.3 TOPICAL DRUG DELIVERY MARKET: REGIONAL MIX
• 4.4 TOPICAL DRUG DELIVERY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
• 4.5 TOPICAL DRUG DELIVERY MARKET: DEVELOPED MARKETS VS. EMERGING ECONOMIES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Increasing prevalence of skin disorders
    • 5.2.1.2 High incidence of burn injuries
    • 5.2.1.3 Growing emphasis on patient convenience
    • 5.2.1.4 Increasing investments in pharmaceutical R&D
    • 5.2.1.5 Rising incidence of chronic diseases
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Adverse skin reactions & allergies
    • 5.2.2.2 Drug failure & recalls of TDD systems
    • 5.2.2.3 High development costs of topical drug delivery products
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Growing preference for self-administration and home care
    • 5.2.3.2 High growth potential of emerging economies
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Technical barriers related to skin irritation & permeability
• 5.3 INDUSTRY TRENDS
  • 5.3.1 ADVANCES IN TRANSDERMAL DRUG DELIVERY SYSTEMS
  • 5.3.2 EMERGENCE OF MICRONEEDLE PATCH TECHNOLOGIES
• 5.4 TECHNOLOGY ANALYSIS
  • 5.4.1 KEY TECHNOLOGIES
    • 5.4.1.1 Nanocarrier-based delivery systems
    • 5.4.1.2 Microemulsions & nanoemulsion
    • 5.4.1.3 Thermosensitive & pH-sensitive hydrogels & hydrocolloids
  • 5.4.2 COMPLEMENTARY TECHNOLOGIES
    • 5.4.2.1 Microneedle-enhanced delivery
    • 5.4.2.2 AI-assisted formulations & prediction models
  • 5.4.3 ADJACENT TECHNOLOGIES
    • 5.4.3.1 Wearable sensor-integrated topical patches
    • 5.4.3.2 3D testing skin models
• 5.5 PORTER'S FIVE FORCES ANALYSIS
  • 5.5.1 THREAT OF NEW ENTRANTS
  • 5.5.2 THREAT OF SUBSTITUTES
  • 5.5.3 BARGAINING POWER OF SUPPLIERS
  • 5.5.4 BARGAINING POWER OF BUYERS
  • 5.5.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.6 REGULATORY LANDSCAPE
  • 5.6.1 REGULATORY ANALYSIS
  • 5.6.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.7 PATENT ANALYSIS
  • 5.7.1 PATENT PUBLICATION TRENDS FOR TOPICAL DRUG DELIVERY
  • 5.7.2 INSIGHTS: JURISDICTION & TOP APPLICANT ANALYSIS
• 5.8 TRADE ANALYSIS
  • 5.8.1 TRADE DATA FOR HS CODE 300490
    • 5.8.1.1 Import data for HS Code 300490
    • 5.8.1.2 Export data for HS Code 300490
• 5.9 PRICING ANALYSIS
  • 5.9.1 AVERAGE SELLING PRICE TREND, BY PRODUCT, 2022-2024
  • 5.9.2 AVERAGE SELLING PRICE OF OINTMENTS, BY KEY PLAYER, 2024
  • 5.9.3 AVERAGE SELLING PRICE OF GELS, BY KEY PLAYER, 2024
  • 5.9.4 AVERAGE SELLING PRICE, BY REGION
  • 5.9.5 AVERAGE SELLING PRICE OF SEMI-SOLID FORMULATIONS, BY REGION, 2024
    • 5.9.5.1 Average selling price trend of ointments, by region, 2022-2024
    • 5.9.5.2 Average selling price trend of creams, by region, 2022-2024
    • 5.9.5.3 Average selling price trend of gels, by region, 2022-2024
• 5.10 REIMBURSEMENT ANALYSIS
• 5.11 KEY CONFERENCES & EVENTS, 2025-2026
• 5.12 KEY STAKEHOLDERS & BUYING CRITERIA
  • 5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.12.2 BUYING CRITERIA
• 5.13 UNMET NEEDS/END-USER EXPECTATIONS
• 5.14 IMPACT OF AI ON TOPICAL DRUG DELIVERY MARKET
  • 5.14.1 AI-USE CASES
• 5.15 PIPELINE ANALYSIS
• 5.16 ECOSYSTEM MARKET MAP
• 5.17 VALUE CHAIN ANALYSIS
• 5.18 INVESTMENT & FUNDING SCENARIO
• 5.19 TRUMP TARIFF IMPACT ON TOPICAL DRUG DELIVERY MARKET
  • 5.19.1 INTRODUCTION
  • 5.19.2 KEY TARIFF RATES
  • 5.19.3 PRICE IMPACT ANALYSIS
  • 5.19.4 KEY IMPACT ON VARIOUS REGIONS
  • 5.19.5 END-USE INDUSTRY IMPACT

6 TOPICAL DRUG DELIVERY MARKET, BY PRODUCT

• 6.1 INTRODUCTION
• 6.2 SEMI-SOLID FORMULATIONS
  • 6.2.1 OINTMENTS
    • 6.2.1.1 Wide applications in analgesic indications to drive market
  • 6.2.2 CREAMS
    • 6.2.2.1 High absorption capabilities to boost demand
  • 6.2.3 LOTIONS
    • 6.2.3.1 Convenient application to fuel uptake
  • 6.2.4 GELS
    • 6.2.4.1 Enhanced patient compliance and aesthetic appeal to drive market
  • 6.2.5 PASTES
    • 6.2.5.1 Prevention of skin irritation to fuel uptake
• 6.3 LIQUID FORMULATIONS
  • 6.3.1 SUSPENSIONS
    • 6.3.1.1 Higher rate of bioavailability and controlled onset of action to drive market
  • 6.3.2 EMULSIONS
    • 6.3.2.1 Versatile carriers for enhanced drug delivery to fuel uptake
  • 6.3.3 SOLUTIONS
    • 6.3.3.1 Uniform & rapid drug delivery to boost demand
• 6.4 SOLID FORMULATIONS
  • 6.4.1 POWDERS
    • 6.4.1.1 Inexpensive manufacturing and effectiveness against antifungal infections to propel market
  • 6.4.2 SUPPOSITORIES
    • 6.4.2.1 Ability to ensure drug compatibility to fuel market
  • 6.4.3 FILM
    • 6.4.3.1 Next-generation advancements to boost demand
• 6.5 TRANSDERMAL PRODUCTS
  • 6.5.1 TRANSDERMAL PATCHES
    • 6.5.1.1 Drug-in-adhesive patches
      • 6.5.1.1.1 Enhanced drug release to fuel uptake
    • 6.5.1.2 Matrix patches
      • 6.5.1.2.1 Rising technological advancements to boost demand
    • 6.5.1.3 Reservoir membrane patches
      • 6.5.1.3.1 Prolonged drug delivery to fuel market
    • 6.5.1.4 Microneedle patches
      • 6.5.1.4.1 Ability to deliver APIs to support market growth
    • 6.5.1.5 Iontophoresis patches
      • 6.5.1.5.1 Low molecular weight patches to support market growth
    • 6.5.1.6 Vapor patches
      • 6.5.1.6.1 Ability to release essential oils to support market growth
  • 6.5.2 TRANSDERMAL GELS
    • 6.5.2.1 Rapid release of drugs to fuel uptake
  • 6.5.3 TRANSDERMAL SPRAYS
    • 6.5.3.1 Targeted approach to boost demand
• 6.6 OTHER PRODUCTS

7 TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION

• 7.1 INTRODUCTION
• 7.2 DERMAL DRUG DELIVERY
  • 7.2.1 STANDARD MEDIUM WITH HIGH DRUG ABSORPTION TO PROPEL MARKET
• 7.3 OPHTHALMIC DRUG DELIVERY
  • 7.3.1 FOCUS ON MICROEMULSION-BASED FORMULATIONS TO BOOST DEMAND
• 7.4 VAGINAL DRUG DELIVERY
  • 7.4.1 LIMITED INTERVENTION BY MEDICAL PERSONNEL TO DRIVE MARKET
• 7.5 RECTAL DRUG DELIVERY
  • 7.5.1 COMBINATION OF LOCAL & SYSTEMIC THERAPY OF DRUGS TO FUEL UPTAKE
• 7.6 NASAL DRUG DELIVERY
  • 7.6.1 QUICK ONSET OF DRUG ACTION & CONVENIENCE TO SUPPORT MARKET UPTAKE

8 TOPICAL DRUG DELIVERY MARKET, BY END USER

• 8.1 INTRODUCTION
• 8.2 HOME CARE SETTINGS
  • 8.2.1 HIGH PREFERENCE, AFFORDABILITY, AND CONVENIENCE TO PROPEL MARKET
• 8.3 HOSPITALS & CLINICS
  • 8.3.1 ADOPTION OF TOPICAL ANAESTHETICS FOR MEDICAL & SURGICAL SUB-SPECIALTIES TO DRIVE MARKET
• 8.4 AMBULATORY SURGERY CENTERS
  • 8.4.1 UTILIZATION OF ANTIMICROBIAL TOPICAL DRUGS FOR TRAUMA CASES TO BOOST DEMAND
• 8.5 BURN CARE CENTERS
  • 8.5.1 HIGH INCIDENCE OF BURN INJURIES AND UPTAKE OF OINTMENTS TO SUPPORT MARKET GROWTH
• 8.6 OTHER END USERS

9 TOPICAL DRUG DELIVERY MARKET, BY REGION

• 9.1 INTRODUCTION
• 9.2 NORTH AMERICA
  • 9.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 9.2.2 US
    • 9.2.2.1 Rising prevalence of skin diseases to drive market
  • 9.2.3 CANADA
    • 9.2.3.1 Rising prevalence of hypertension and funding for topical drugs research to drive market growth
• 9.3 EUROPE
  • 9.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 9.3.2 GERMANY
    • 9.3.2.1 Growing focus of R&D for pharmaceutical API development to boost demand
  • 9.3.3 UK
    • 9.3.3.1 Rising demand for painless treatment alternatives to fuel market
  • 9.3.4 FRANCE
    • 9.3.4.1 Rising incidence of diabetes and subsequent increase in skin lesions to drive market
  • 9.3.5 ITALY
    • 9.3.5.1 Rising demand for transdermal patches to propel market
  • 9.3.6 SPAIN
    • 9.3.6.1 Expanding research hub to fuel market
  • 9.3.7 NETHERLANDS
    • 9.3.7.1 Public awareness initiatives for preventive care to fuel uptake
  • 9.3.8 REST OF EUROPE
• 9.4 ASIA PACIFIC
  • 9.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 9.4.2 CHINA
    • 9.4.2.1 Rising cases of communicable diseases to drive market
  • 9.4.3 JAPAN
    • 9.4.3.1 Increasing number of product approvals to drive market
  • 9.4.4 INDIA
    • 9.4.4.1 Growing focus on adoption of non-invasive drug delivery methods to drive market
  • 9.4.5 AUSTRALIA
    • 9.4.5.1 Increasing number of smokers to fuel uptake
  • 9.4.6 SOUTH KOREA
    • 9.4.6.1 Favorable government focus on expanding clinical trials to boost demand
  • 9.4.7 THAILAND
    • 9.4.7.1 Regulatory reforms and supportive healthcare initiatives to support market growth
  • 9.4.8 VIETNAM
    • 9.4.8.1 Increasing investments and regulatory reforms to fuel uptake
  • 9.4.9 REST OF ASIA PACIFIC
• 9.5 LATIN AMERICA
  • 9.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 9.5.2 BRAZIL
    • 9.5.2.1 High prevalence of diabetes to propel market growth
  • 9.5.3 MEXICO
    • 9.5.3.1 Increasing prevalence of glaucoma to drive market
  • 9.5.4 REST OF LATIN AMERICA
• 9.6 MIDDLE EAST & AFRICA
  • 9.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
  • 9.6.2 GCC COUNTRIES
    • 9.6.2.1 Kingdom of Saudi Arabia (KSA)
      • 9.6.2.1.1 Expanding healthcare infrastructure to boost demand
    • 9.6.2.2 United Arab Emirates (UAE)
      • 9.6.2.2.1 Increasing prevalence of diabetes to fuel uptake
    • 9.6.2.3 Other GCC Countries
  • 9.6.3 REST OF MIDDLE EAST & AFRICA

10 COMPETITIVE LANDSCAPE

• 10.1 OVERVIEW
• 10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 10.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN TOPICAL DRUG DELIVERY MARKET
• 10.3 REVENUE ANALYSIS, 2020-2024
• 10.4 MARKET SHARE ANALYSIS
  • 10.4.1 RANKING OF KEY MARKET PLAYERS
• 10.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  • 10.5.1 STARS
  • 10.5.2 EMERGING LEADERS
  • 10.5.3 PERVASIVE PLAYERS
  • 10.5.4 PARTICIPANTS
  • 10.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
    • 10.5.5.1 Company footprint
    • 10.5.5.2 Region footprint
    • 10.5.5.3 Product footprint
    • 10.5.5.4 Site of application footprint
• 10.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
  • 10.6.1 PROGRESSIVE COMPANIES
  • 10.6.2 RESPONSIVE COMPANIES
  • 10.6.3 DYNAMIC COMPANIES
  • 10.6.4 STARTING BLOCKS
  • 10.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
    • 10.6.5.1 Detailed list of key startups/SME players
    • 10.6.5.2 Competitive benchmarking of key emerging players/startups
• 10.7 BRAND/PRODUCT COMPARISON
  • 10.7.1 TOPICAL DRUG DELIVERY MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
• 10.8 R&D EXPENDITURE OF KEY PLAYERS
  • 10.8.1 R&D EXPENDITURE OF KEY PLAYERS IN TOPICAL DRUG DELIVERY MARKET
• 10.9 COMPANY VALUATION & FINANCIAL METRICS
  • 10.9.1 FINANCIAL METRICS
  • 10.9.2 COMPANY VALUATION
• 10.10 COMPETITIVE SCENARIO
  • 10.10.1 PRODUCT LAUNCHES, ENHANCEMENTS, AND APPROVALS
  • 10.10.2 DEALS
  • 10.10.3 EXPANSIONS
  • 10.10.4 OTHER DEVELOPMENTS

11 COMPANY PROFILES

• 11.1 KEY PLAYERS
  • 11.1.1 JOHNSON & JOHNSON SERVICES, INC.
    • 11.1.1.1 Business overview
    • 11.1.1.2 Products offered
    • 11.1.1.3 Recent developments
      • 11.1.1.3.1 Product approvals
      • 11.1.1.3.2 Deals
    • 11.1.1.4 MnM view
      • 11.1.1.4.1 Key strengths
      • 11.1.1.4.2 Strategic choices
      • 11.1.1.4.3 Weaknesses & competitive threats
  • 11.1.2 GALDERMA
    • 11.1.2.1 Business overview
    • 11.1.2.2 Products offered
    • 11.1.2.3 Recent developments
      • 11.1.2.3.1 Product launches & approvals
      • 11.1.2.3.2 Deals
      • 11.1.2.3.3 Expansions
    • 11.1.2.4 MnM view
      • 11.1.2.4.1 Key strengths
      • 11.1.2.4.2 Strategic choices
      • 11.1.2.4.3 Weaknesses & competitive threats
  • 11.1.3 BAYER AG
    • 11.1.3.1 Business overview
    • 11.1.3.2 Products offered
    • 11.1.3.3 Recent developments
      • 11.1.3.3.1 Product launches & approvals
      • 11.1.3.3.2 Deals
    • 11.1.3.4 MnM view
      • 11.1.3.4.1 Key strengths
      • 11.1.3.4.2 Strategic choices
      • 11.1.3.4.3 Weaknesses & competitive threats
  • 11.1.4 NOVARTIS AG
    • 11.1.4.1 Business overview
    • 11.1.4.2 Products offered
    • 11.1.4.3 Recent developments
      • 11.1.4.3.1 Deals
      • 11.1.4.3.2 Other developments
    • 11.1.4.4 MnM view
      • 11.1.4.4.1 Key strengths
      • 11.1.4.4.2 Strategic choices
      • 11.1.4.4.3 Weaknesses & competitive threats
  • 11.1.5 ABBVIE INC.
    • 11.1.5.1 Business overview
    • 11.1.5.2 Products offered
    • 11.1.5.3 Recent developments
      • 11.1.5.3.1 Product launches
      • 11.1.5.3.2 Expansions
      • 11.1.5.3.3 Other developments
    • 11.1.5.4 MnM view
      • 11.1.5.4.1 Key strengths
      • 11.1.5.4.2 Strategic choices
      • 11.1.5.4.3 Weaknesses & competitive threats
  • 11.1.6 GLENMARK PHARMACEUTICALS LIMITED
    • 11.1.6.1 Business overview
    • 11.1.6.2 Products offered
    • 11.1.6.3 Recent developments
      • 11.1.6.3.1 Product approvals
      • 11.1.6.3.2 Deals
  • 11.1.7 GSK PLC.
    • 11.1.7.1 Business overview
    • 11.1.7.2 Products offered
    • 11.1.7.3 Recent developments
      • 11.1.7.3.1 Deals
      • 11.1.7.3.2 Other developments
  • 11.1.8 BAUSCH HEALTH COMPANIES INC.
    • 11.1.8.1 Business overview
    • 11.1.8.2 Products offered
    • 11.1.8.3 Recent developments
      • 11.1.8.3.1 Product launches & approvals
      • 11.1.8.3.2 Deals
  • 11.1.9 HISAMITSU PHARMACEUTICAL CO., INC.
    • 11.1.9.1 Business overview
    • 11.1.9.2 Products offered
    • 11.1.9.3 Recent developments
      • 11.1.9.3.1 Product launches, enhancements, and approvals
      • 11.1.9.3.2 Deals
      • 11.1.9.3.3 Expansions
  • 11.1.10 CIPLA
    • 11.1.10.1 Business overview
    • 11.1.10.2 Products offered
    • 11.1.10.3 Recent developments
      • 11.1.10.3.1 Deals
  • 11.1.11 VIATRIS INC.
    • 11.1.11.1 Business overview
    • 11.1.11.2 Products offered
    • 11.1.11.3 Recent developments
      • 11.1.11.3.1 Product launches & approvals
      • 11.1.11.3.2 Deals
      • 11.1.11.3.3 Other developments
  • 11.1.12 ORGANON GROUP OF COMPANIES
    • 11.1.12.1 Business overview
    • 11.1.12.2 Products offered
    • 11.1.12.3 Recent developments
      • 11.1.12.3.1 Product approvals
      • 11.1.12.3.2 Deals
  • 11.1.13 PFIZER, INC.
    • 11.1.13.1 Business overview
    • 11.1.13.2 Products offered
    • 11.1.13.3 Recent developments
      • 11.1.13.3.1 Product approvals
      • 11.1.13.3.2 Deals
  • 11.1.14 CRESCITA THERAPEUTICS INC.
    • 11.1.14.1 Business overview
    • 11.1.14.2 Products offered
    • 11.1.14.3 Recent developments
      • 11.1.14.3.1 Deals
      • 11.1.14.3.2 Other developments
  • 11.1.15 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    • 11.1.15.1 Business overview
    • 11.1.15.2 Products offered
    • 11.1.15.3 Recent developments
      • 11.1.15.3.1 Deals
      • 11.1.15.3.2 Expansions
  • 11.1.16 TEVA PHARMACEUTICAL INDUSTRIES LTD.
    • 11.1.16.1 Business overview
    • 11.1.16.2 Products offered
    • 11.1.16.3 Recent developments
      • 11.1.16.3.1 Deals
  • 11.1.17 SOLVENTUM
    • 11.1.17.1 Business overview
    • 11.1.17.2 Products offered
    • 11.1.17.3 Recent developments
      • 11.1.17.3.1 Deals
  • 11.1.18 LUYE PHARMA GROUP
    • 11.1.18.1 Business overview
    • 11.1.18.2 Products offered
    • 11.1.18.3 Recent developments
      • 11.1.18.3.1 Product approvals
      • 11.1.18.3.2 Deals
  • 11.1.19 LEAD CHEMICAL CO., LTD.
    • 11.1.19.1 Business overview
    • 11.1.19.2 Products offered
  • 11.1.20 PURDUE PHARMA L.P.
    • 11.1.20.1 Business overview
    • 11.1.20.2 Products offered
  • 11.1.21 LAVIPHARM
    • 11.1.21.1 Business overview
    • 11.1.21.2 Products offered
• 11.2 OTHER PLAYERS
  • 11.2.1 CMP PHARMA, INC.
  • 11.2.2 ENCORE DERMATOLOGY, INC.
  • 11.2.3 RUSAN PHARMA LTD.
  • 11.2.4 ADHEXPHARMA

12 APPENDIX

• 12.1 DISCUSSION GUIDE
• 12.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 12.3 RELATED REPORTS
• 12.4 AUTHOR DETAILS